Synergy Pharmaceuticals to Present at Piper Jaffray Healthcare Conference

Synergy Pharmaceuticals to Present at Piper Jaffray Healthcare Conference

NEW YORK, Nov. 21, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc.
(Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders
and diseases, today announced that its President and CEO, Gary S. Jacob, Ph.D,
will present at the 24th Annual Piper Jaffray Healthcare Conference on
Tuesday, November 27, 2012 at 12:30 p.m. EST at the New York Palace Hotel in
New York, NY.

The webcast presentation can be accessed via the Investor Relations section of
the company's website at www.synergypharma.com.

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs
to treat gastrointestinal disorders and diseases. Synergy's lead proprietary
drug candidate plecanatide is a synthetic analog of the human gastrointestinal
(GI) hormone uroguanylin, and functions by activating the guanylate cyclase C
receptor on epithelial cells of the GI tract. Synergy completed a Phase I
study of plecanatide in healthy volunteers and a Phase IIa clinical trial in
chronic idiopathic constipation (CIC) patients. In October, 2011, Synergy
initiated dosing of patients in a major Phase IIb/III clinical trial of
plecanatide to treat CIC. Plecanatide is also being developed to treat
constipation-predominant irritable bowel syndrome (IBS-C), with the first
trial in IBS-C patients planned for the second half of 2012. Synergy's second
GC-C agonist SP-333 is in clinical development to treat inflammatory bowel
diseases, and is presently in a Phase I trial in healthy volunteers. More
information is available at http://www.synergypharma.com.

CONTACT: Danielle Spangler
         The Trout Group
         synergy@troutgroup.com
         (646) 378-2924